Robbie Marcus
Stock Analyst at JP Morgan
(3.97)
# 530
Out of 4,868 analysts
161
Total ratings
55.45%
Success rate
8.62%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Downgrades: Neutral | $110 → $76 | $69.81 | +8.87% | 5 | May 30, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $10.60 | +50.94% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $5.84 | +19.86% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $90.55 | +15.96% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $11.91 | +0.76% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $129.70 | +50.35% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $52.08 | +11.37% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $13.87 | +22.57% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $92.95 | +29.10% | 1 | Mar 28, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $29.80 | +20.81% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $373.26 | +19.22% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $509.49 | +32.49% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.43 | +102.33% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $101.37 | +8.51% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $301.79 | +9.35% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $17.83 | +79.47% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $31.57 | +26.70% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $73.98 | +5.43% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $81.01 | +4.93% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $71.89 | +25.19% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $30.66 | +63.08% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $5.46 | +46.52% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $257.01 | -2.73% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $8.61 | +85.83% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.62 | +5.74% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $11.55 | +47.19% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $132.41 | -10.88% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $145.53 | +7.19% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $85.73 | +22.48% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $102.34 | -60.91% | 2 | May 5, 2020 |
The Cooper Companies
May 30, 2025
Downgrades: Neutral
Price Target: $110 → $76
Current: $69.81
Upside: +8.87%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $10.60
Upside: +50.94%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $5.84
Upside: +19.86%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $90.55
Upside: +15.96%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $11.91
Upside: +0.76%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $129.70
Upside: +50.35%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $52.08
Upside: +11.37%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $13.87
Upside: +22.57%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $92.95
Upside: +29.10%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $29.80
Upside: +20.81%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $373.26
Upside: +19.22%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $509.49
Upside: +32.49%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.43
Upside: +102.33%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $101.37
Upside: +8.51%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $301.79
Upside: +9.35%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $17.83
Upside: +79.47%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $31.57
Upside: +26.70%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $73.98
Upside: +5.43%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $81.01
Upside: +4.93%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $71.89
Upside: +25.19%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $30.66
Upside: +63.08%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $5.46
Upside: +46.52%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $257.01
Upside: -2.73%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $8.61
Upside: +85.83%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.62
Upside: +5.74%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $11.55
Upside: +47.19%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $132.41
Upside: -10.88%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $145.53
Upside: +7.19%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $85.73
Upside: +22.48%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $102.34
Upside: -60.91%